Design, synthesis, and biologic evaluation of novel chrysin derivatives as cytotoxic agents and caspase-3/7 activators. 2019

Buthina Abdallah Al-Oudat, and Mohammad Ali Alqudah, and Suaad Abdallah Audat, and Qosay Ali Al-Balas, and Tamam El-Elimat, and Mohammad Abdelhafeez Hassan, and Islam Nawaf Frhat, and Marwah Mohammad Azaizeh
Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Jordan University of Science and Technology, Irbid 22110, Jordan, baoudat@just.edu.jo.

BACKGROUND Chrysin (5,7-dihydroxyflavone) is a widely distributed natural flavonoid found in many plant extracts, honey and propolis. Several studies revealed that chrysin possesses multiple biological activities including anti-cancer effects. It has been established that activation of apoptosis is the key molecular mechanism responsible for the cytotoxic potential of chrysin. The objective of this study was to design and synthesize potent chrysin analogues as potential cytotoxic agents. METHODS A series of chrysin derivatives (3a-m) bearing N'-alkylidene/arylideneacetohydrazide moiety were designed, synthesized, and evaluated for their antiproliferative activity against two human breast cancer cell lines, MDA-MB-231 and MCF-7 by applying the MTT colorimetric assay. Selected compounds were tested for their ability to induce apoptosis through caspase 3/7 activation in MDA-MB-231 cells only since MCF-7 cells lack procaspase 3. RESULTS Compounds (3a-m) were obtained as geometrical isomers (E/Z isomers) in good yields upon treatment of hydrazide 5 with different aliphatic and aromatic aldehydes. Most of the synthesized compounds demonstrated moderate-to-good activity against both cell lines. The cytotoxicity results revealed the importance of lipophilic moieties at C-4 position of ring D in imparting the cytotoxic activities to the compounds. Compound 3e with 4-benzyloxy substituent was found to be the most active among the synthesized compounds with IC50 3.3 µM against MDA-MB-231 and 4.2 µM against MCF-7 cell lines. The cytotoxic potential of compound 3e is comparable to that of the well-known anti-cancer agent doxorubicin. In addition, compounds substituted with fluoro (3b), nitro (3h), and dimethylamino (3j) exhibited good cytotoxicity with IC50 <6.5 µM against MDA-MB-231 and <12 µM against MCF-7. Selected compounds were able to induce apoptosis in MDA-MB-231 cells as indicated by caspase-3 and/or -7 activation. CONCLUSIONS Our results show that the newly designed chrysin derivatives exert anticancer activity in human breast cancer cell lines, MDA-MB-231 and MCF-7. Therefore, they can be considered as leads for further development of more potent and selective cytotoxic agents.

UI MeSH Term Description Entries
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D004789 Enzyme Activation Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme. Activation, Enzyme,Activations, Enzyme,Enzyme Activations
D005419 Flavonoids A group of phenyl benzopyrans named for having structures like FLAVONES. 2-Phenyl-Benzopyran,2-Phenyl-Chromene,Bioflavonoid,Bioflavonoids,Flavonoid,2-Phenyl-Benzopyrans,2-Phenyl-Chromenes,2 Phenyl Benzopyran,2 Phenyl Benzopyrans,2 Phenyl Chromene,2 Phenyl Chromenes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular

Related Publications

Buthina Abdallah Al-Oudat, and Mohammad Ali Alqudah, and Suaad Abdallah Audat, and Qosay Ali Al-Balas, and Tamam El-Elimat, and Mohammad Abdelhafeez Hassan, and Islam Nawaf Frhat, and Marwah Mohammad Azaizeh
April 2019, European journal of medicinal chemistry,
Buthina Abdallah Al-Oudat, and Mohammad Ali Alqudah, and Suaad Abdallah Audat, and Qosay Ali Al-Balas, and Tamam El-Elimat, and Mohammad Abdelhafeez Hassan, and Islam Nawaf Frhat, and Marwah Mohammad Azaizeh
July 2020, Advanced pharmaceutical bulletin,
Buthina Abdallah Al-Oudat, and Mohammad Ali Alqudah, and Suaad Abdallah Audat, and Qosay Ali Al-Balas, and Tamam El-Elimat, and Mohammad Abdelhafeez Hassan, and Islam Nawaf Frhat, and Marwah Mohammad Azaizeh
April 2006, Archiv der Pharmazie,
Buthina Abdallah Al-Oudat, and Mohammad Ali Alqudah, and Suaad Abdallah Audat, and Qosay Ali Al-Balas, and Tamam El-Elimat, and Mohammad Abdelhafeez Hassan, and Islam Nawaf Frhat, and Marwah Mohammad Azaizeh
April 2013, Drug research,
Buthina Abdallah Al-Oudat, and Mohammad Ali Alqudah, and Suaad Abdallah Audat, and Qosay Ali Al-Balas, and Tamam El-Elimat, and Mohammad Abdelhafeez Hassan, and Islam Nawaf Frhat, and Marwah Mohammad Azaizeh
December 2018, Natural product research,
Buthina Abdallah Al-Oudat, and Mohammad Ali Alqudah, and Suaad Abdallah Audat, and Qosay Ali Al-Balas, and Tamam El-Elimat, and Mohammad Abdelhafeez Hassan, and Islam Nawaf Frhat, and Marwah Mohammad Azaizeh
October 2015, Chemical biology & drug design,
Buthina Abdallah Al-Oudat, and Mohammad Ali Alqudah, and Suaad Abdallah Audat, and Qosay Ali Al-Balas, and Tamam El-Elimat, and Mohammad Abdelhafeez Hassan, and Islam Nawaf Frhat, and Marwah Mohammad Azaizeh
November 2021, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences,
Buthina Abdallah Al-Oudat, and Mohammad Ali Alqudah, and Suaad Abdallah Audat, and Qosay Ali Al-Balas, and Tamam El-Elimat, and Mohammad Abdelhafeez Hassan, and Islam Nawaf Frhat, and Marwah Mohammad Azaizeh
February 2010, Bioorganic & medicinal chemistry,
Buthina Abdallah Al-Oudat, and Mohammad Ali Alqudah, and Suaad Abdallah Audat, and Qosay Ali Al-Balas, and Tamam El-Elimat, and Mohammad Abdelhafeez Hassan, and Islam Nawaf Frhat, and Marwah Mohammad Azaizeh
July 2020, Natural product research,
Buthina Abdallah Al-Oudat, and Mohammad Ali Alqudah, and Suaad Abdallah Audat, and Qosay Ali Al-Balas, and Tamam El-Elimat, and Mohammad Abdelhafeez Hassan, and Islam Nawaf Frhat, and Marwah Mohammad Azaizeh
December 2020, BMC chemistry,
Copied contents to your clipboard!